NCT07052448Enrolling by invitation
The Efficacy of Sequential RT After Triple Therapy for uHCC
The Efficacy of Sequential Radiotherapy After the Combination of Transcatheter Arterial Chemoembolization With Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 4 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Triple therapy of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies has demonstrated excellent efficacy in unresectable hepatocellular carcinoma (uHCC). However, tumor drug resistance is still a major problem and many patients fail to achieve complete necrosis of the lesions after treatment. This study aimed to investigate the efficacy and safety of sequential radiotherapy after triple therapy in patients with uHCC to improve tumor response rate.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 35 (estimated)
- First submitted
- 21 Jun 2025
- Start date
- 1 Nov 2020
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- Fujian Provincial Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07052448
What you commit to
- Study type: Observational
- Planned participants: 35
- From 1 Nov 2020 to the primary completion date, 1 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous acceptance of other antitumor treatments
- Treatment in conjunction with other treatment regimens, such as radiofrequency ablation and chemotherapy
Other illness
- History of other malignancies
Other
- Incomplete data.
Who the study is looking for
- Patients diagnosed with HCC and assessed as unresectable by multidisciplinary team (MDT)
- Patients who achieved PR or SD after triple therapy according to the mRECIST and did not meet the criteria for radical surgical resection or could not tolerate surgical treatment
- Patients who received sequential radiotherapy
- Age between 18 and 75 years
- Child-Pugh class A or B
- Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-1
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuzhou University Affiliated Provincial Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.